Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Short term Debt: 2010-2022

Historic Short term Debt for Anika Therapeutics (ANIK) over the last 4 years, with Jun 2022 value amounting to $4.3 million.

  • Anika Therapeutics' Short term Debt fell 74.42% to $4.3 million in Q2 2022 from the same period last year, while for Jun 2022 it was $4.3 million, marking a year-over-year decrease of 74.42%. This contributed to the annual value of $4.3 million for FY2021, which is 67.04% down from last year.
  • According to the latest figures from Q2 2022, Anika Therapeutics' Short term Debt is $4.3 million, which was up 0.35% from $4.3 million recorded in Q1 2022.
  • In the past 5 years, Anika Therapeutics' Short term Debt ranged from a high of $24.8 million in Q1 2021 and a low of $4.3 million during Q3 2021.
  • Its 3-year average for Short term Debt is $10.3 million, with a median of $4.3 million in 2022.
  • Data for Anika Therapeutics' Short term Debt shows a maximum YoY slumped of 82.68% (in 2022) over the last 5 years.
  • Over the past 3 years, Anika Therapeutics' Short term Debt (Quarterly) stood at $13.1 million in 2020, then tumbled by 67.04% to $4.3 million in 2021, then plummeted by 74.42% to $4.3 million in 2022.
  • Its Short term Debt stands at $4.3 million for Q2 2022, versus $4.3 million for Q1 2022 and $4.3 million for Q4 2021.